- Active not recruitingPHASE1
POTENT - Tepotinib in Combination With Pembrolizumab in NSCLC
This study combines two drugs, tepotinib and pembrolizumab, for advanced non-small cell lung cancer. It explores if tepotinib can make immunotherapy like pembrolizumab more effective, especially for cancers that usually don't respond well to such treatments.
For: Advanced Cancer · Non Small Cell Lung CancerUnited Kingdom - Ongoing, recruitingTherapeutic exploratory (Phase II)
A Phase II, two-arm study to investigate tepotinib combined with osimertinib in MET amplified, advanced or metastatic non-small cell lung cancer (NSCLC) harboring activating EGFR mutations and having acquired resistance to prior osimertinib therapy (INSIGHT 2 Study)
This study is for people with a certain type of advanced lung cancer that has stopped responding to a previous treatment called osimertinib. It tests a new combination of two drugs, tepotinib and osimertinib, to see if it can shrink tumours.
For: Lung CancerItaly · France · Belgium - Ongoing, recruitingTherapeutic exploratory (Phase II)
A Phase II, single-arm trial to investigate tepotinib in advanced (locally advanced or metastatic) non-small cell lung cancer with MET exon 14 (METex14) skipping alterations or MET amplification (VISION)
This study is looking at a new medicine called tepotinib for certain types of advanced lung cancer. It aims to see how well it shrinks tumours in people with specific changes in their cancer cells (METex14 skipping or MET amplification).
For: Lung CancerBelgium · France · Poland - AuthorisedTherapeutic exploratory (Phase II)
Phase 2, open-label, multicentre, single-arm study to evaluate the activity of the combination of EGFR inhibitors and c-MET inhibitors in patients with platinum-resistant head and neck squamous cell carcinoma after relapse to immunotherapy.
This study is for people in the UK with head and neck cancer that has come back after other treatments. It's testing a new combination of two drugs, cetuximab and tepotinib, to see if they can shrink the cancer. It's called a 'Phase 2' study, meaning it's an early look at how well the treatment works.
For: Head and neck cancerItaly